Table 1.

Major clinical trials of stem cell therapy in acute myocardial infarction (MI)

Study	Number of patients Treated / control	Time of delivery post-MI (days)	Treatment, route of administration and cell type	Results
Strauer et al 2002 [46]	10/10	5 to 9	IC, BM-MNC	Decreased infarct size, improved regional wall motion and perfusion. No change in EF or LVEDV
TOPCARE-AMI [33,34,47]	29 MNC 30 CPC 11 control	3 to 7	IC, CPC or BM-MNC	Significant increase in EF, improved regional wall motion, reduced infarct size, no change in LVEDV
BOOST [31,32]	30/30	6	IC, BM-MNC	Improved EF at 6 months, No difference at 18 months
FIRST-LINE-AMI [40]	25/25	0 to 6	Mobilization by G-CSF	Improved EF and remodeling at 4 months
REPAIR-AMI [36]	102/102	4	IC, BM-MNC	Improved EF and reduced infarct size at 4 months
ASTAMI [38]	100	5 to 8	IC, BM-MNC	No difference at 6 months
Chen et al 2004 [37]	34/35	18	IC, MSC	Improved and perfusion at 6 months
JANSSENS et al 2006 [39]	33/34	1	IC, BM-MNC	No effect
REVIVAL [41]	56/58	0 to 5	Mobilization by G-CSF	No difference at 6 months
STEMMI [42]	39/39	0 to 6	Mobilization by G-CSF	No difference at 6 months

IC: intra-coronary, BM-MNC: Bone marrow-derived mononuclear cells, CPC: circulating blood-derived progenitor cells EF: ejection fraction, LVEDV: left ventricular end-diastolic volume